← Back to Search

Epinephrine Alternative

Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

Phase 2
Waitlist Available
Research Sponsored by ARS Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (timepoints 0) to 1 hour

Summary

This trial is testing a needle-free way to give epinephrine to people with severe asthma who aren't helped by other treatments.

Eligible Conditions
  • Asthma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (timepoints 0) to 1 hour
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (timepoints 0) to 1 hour for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Effect of ARS-1 versus Albuterol and placebo

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: 1 mg/100 µL dose of ARS-1Active Control1 Intervention
Group II: 2 mg/100 µL dose of ARS-1Active Control1 Intervention
Group III: albuterol MDI (180 mcg)Active Control1 Intervention
Group IV: placeboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

ARS Pharmaceuticals, Inc.Lead Sponsor
2 Previous Clinical Trials
39 Total Patients Enrolled
Sarina Tanimoto, MD, PhDStudy DirectorARS Pharmaceuticals, Inc.
1 Previous Clinical Trials
24 Total Patients Enrolled
~5 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top